Adusumilli PS, Chan MK, Ben-Porat L, Mullerad M, Stiles BM, Tuorto S, Fong Y. Citation characteristics of basic science research publications in general surgical journals. J Surg Res 2005;128:168-73.
Adusumilli PS, Eisenberg DP, Chun YS, Ryu KW, Ben-Porat L, Hendershott KJ, Chan MK, Huq R, Riedl C, Fong Y. Virally-directed fluorescent imaging (VFI) improves diagnostic sensitivity in the detection of minimal residual disease following potentially curative cytoreductive surgery. J Gastrointest Surg 2005; 9:1138-47.
Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, Larson SM, Fong Y. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005;23:8713-8716.
Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Intl J Rad Oncol Biol Physic 2005;62:111-117.
Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, Espat J, Stojadinovic A, Cohen AM, Fong Y, Paty PB. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005;201:57-65.
Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, Subbaramaiah K, Dannenberg AJ. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-4197.
Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in a trial fibrillation after thoracic surgery independent of C-reactive protein. Chest 2005;128:3421-3427.
Araten DJ, Golde DW, Zhang RH, Thaler HT, Gargiulo L, Notaro R, Luzzatto L. A quantitative measurement of the human somatic mutation rate. Cancer Res 2005;65:8111-8117.
Araten DJ, Thaler HT, Luzzatto L. High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal hemoglobinuria. Thromb Haemost 2005;93:88-91.
Bach PB. Racial disparities and site of care. Ethn Dis 2005;15:S31-S33.
Barrera R, Shi W, Amar D, Thaler HT, Gabovich N, Bains MS, White DA. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. Chest 2005;127:1977-1983.
Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005;23:3552-3561.
Beekman K, Morris M, Slovin S, Heller G, Wilton A, Bianco F Jr. Scardino PT, Scher HI. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. Urology 2005;65:947-952.
Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 2005;4:86-90.
Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample (with editorial). J Nat Cancer Inst 2005;97:1507-1515.
Begg CB. Systematic reviews of diagnostic accuracy studies require study by study examination: first for heterogeneity, and then for sources of heterogeneity. J Clin Epidemiol 2005;58:882-893.
Bennett J, Gönen M, D'Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg 2005;201:503-510.
Bentrem DJ, Okabe S, Wong WD, Guillem JG, Weiser MR, Temple LK, Ben-Porat L, Minsky BD, Cohen AM, Paty PB. T1 Adenocarcinoma of the rectum: transanal excision or radical surgery? Ann Surg 2005;242:472-479.
Bernstein JL, Concannon P, Langholz B, Thompson WD, Bernstein L, Stovall M, Thomas DC, WECARE Study Collaborative Group. Multi-center screening of mutations in the ATM gene among women with breast cancer - the WECARE study. Rad Res 2005;163:698-699.
Bernstein JL, Godbold J, Raptis G, Watson M, Levinson B, Aaronson SA, Flemin TP. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005;11:6528-6535.
Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Barnhill R. Sun exposure and mortality from melanoma. J Natl Cancer Inst. 2005;97:195-199.
Bhargava R, Shia J, Hummer AJ, Thaler HT, Tornos C, Soslow RA. Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains. Mod Pathol 2005;18:40-47.
Bianco FJ Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005;173:2099-2103.
Booth J, Capanu M, Heigenhauser L, Exact conditional p-value calculation for the quasi-symmetry model. J Comp Graph Stat 2005;14:716-725.
Boruchov, AM, Heller G, Veri MC, Bovini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Investigat 2005;115:2914-2923.
Bowne WB, Lee B, Ben-Porat L, Paty PB, Guillem JG, Cohen AM, Enker W, Wong WD, Weiser MR. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum 2005;48:897-909.
Brooks DR, Austin JHM, Heelan R, Ginsberg M, Shin V, Olson SH, Muscat JE, Stellman SD. Influence of type of cigarette on peripheral versus central lung cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:576-581.
Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care (editorial). J Clin Oncol 2005;23:2590-2592.
Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S, Loeb K, Kollmeier M, Smith M, Rosenstein BS. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Intl J Rad Oncol Biol Physic 2005;61:196-202.
Chadalavada RSV, Houldsworth J, Olshen AB, Bosl G, Studer L, Chaganti RSK. Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. Funct Integr Genomics 2005;5:59-69.
Charles CA, Yee VS, Dusza SW, Marghoob AA, OliveriaA, Kopf A, Rigel D, Halpern AC. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists. Arch Dermatol 2005;141:723-729.
Chen W, Houldsworth J, Olshen AB, Nabjangud G, Chaganti S, Venkatraman ES, Halaas J, Teruya-Feldstein J, Zelenetz AD, Chaganti RS. Array comparative genomic hybrization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2005 [Epub ahead of print].
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 20:1803-1810.
D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142.
Dohan D, Schrag D. Using navigators to improve care of underserved patients. Cancer 2005;10:848-855.
Dusza SW, OliveriaA, Geller AC, Marghoob AA, Halpern AC. Student-parent agreement in self-reported sun behaviors. J Am Acad Dermatol. 2005;52:896-900.
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Nat Cancer Inst 2005;97:1407-1427.
Eilber FC, Brennan MF, Riedel E, Alektiar KM, Antonescu CR, Singer S. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas.Ann Surg Oncol 2005;12:228-236.
Eitan R, Saenz CC, Venkatraman ES, Hann L, Bach A, Gretz E, Barakat RR, Chi DS. Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. Menopause 2005;12:27-30.
Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast cancer survival in the U.S. 1975-1999. Cancer 2005;104:1149-1157.
Elkin EB, Weinstein MC, Kuntz KM, Bunnell CA, Weeks JC. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs. Breast Cancer Res and Treatment 2005;93:25-35.
Engel LS, Hill DA, Hoppin JA, Lubin JH, Lynch CF, Pierce J, Samanic C, Sandler DP, Blair A, Alavanja MC. Pesticide use and breast cancer risk among farmers' wives in the Agricultural Health Study. Am J Epidemiol. 2005;161:121-135.
Ferguson SE, Olshen AB, Viale A, Barakat RR, Boyd J. Stratification of intermediate-risk endometrial cancer patients into groups at high or low risk for recurrence based on tumor gene expression profilies. Clin Cancer Res 2005;11: 2252-2257.
Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Multiple primary melanomas: clinicopathologic features and risk factors in 385 patients. J Am Med Assoc 2005;294:1647-1654.
Fong Y, Gönen M, Rubin M, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005;242: 540-547.
Fornier MN, Modi S, Panageas KS, NortonL, Hudis C. incidence of Chemotherapy-induced long-term amenorrhea in breast cancer patients age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104: 1575-1579.
Ghazinouri R, Levy C, Ben-Porat L, Stubblefield MD. Shoulder impairments in patients with breast cancer: a retrospective review. Rehabilitation Oncology 2005;23:5-8.
Gollub MJ, Jhaveri S, Schwartz E, Felderman H, Cooper C, Markowitz AJ, Kurtz RC, Thaler H. CT colonography features of sigmoid diverticular disease. Clinical Imaging 2005;3:200-206.
Gollub MJ, Lefkowitz R, Moskowitz CS, Ilson D, Kelsen D, Felderman H. Pelvic CT in patient with esophageal cancer. Amer J Roentgenol 2005;184:487-490.
Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005;92:965-970.
Gönen M, Johnson WO, Lu T, Westfall PH. The Bayesian two-sample t-test. The Am Stat 2005;59:252-257.
Gönen M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemp Clin Trials. 2005;26:131-140.
Gönen M. Planning a dose-response study when doses are subject-specific. Stat Med 2005;24:2613-2623.
Gonen M. Planning a dose-response study with subject-specific doses. Stat Med. 2005; 24:2613-2623.
Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, Dannenberg AJ, Duffield-Lillico AJ. Levels of PGE-M, the major urinary metabolite of PGE2, are increased in smokers. Clin Cancer Res 2005;11:6087-6093
Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J. Identifying site-specific metastasis genes and functions. Cold Spring Harbor Symposia Quantitative Biology 2005;70:1-10.
Gure AO, Chua R, Williamson B, Gönen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJG, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11 8055-8062.
Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol 2005;173:1513-1517.
Hale E, Stein J, Ben-Porat L, Panageas KS, Eichenbaum MS, Marghoob AA, Osman I, Kopf AW, Polsky D. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry.Br J Dermatol 2005;152:512-517.
Hawkins WG, Busam KJ, Ben Porat L, Panageas KS, Coit DG, Gyorki DE, Linehan DC, Brady MS. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12:207-213.
Hawkins WG, DeMatteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, Gönen M, Blumgart LH. Caudate hepatectomy for cancer: A single institution experience with 150 patients. J Am Coll Surg 2005;200:345-352.
Heller G. Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis. Stat Med 2005; [Epub ahead of print]
Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-1884.
Howard MA, Cordeiro P, Disa J, Samson W, Gönen M, Schoelle H, Mehrara B. Free tissue transfer in the elderly: incidence of perioperative complications following microsurgical reconstruction of 197 septuagenarians and octogenarians. Plastic Reconstructive Surgery. 2005;116:1659-1668.
Howe LR, Chang S, Tolle KC, Dillon R, Young LJT, Newman RA, Yang P, Thaler HT, Muller WJ, Brown AMC, Hla T, Subbaramaiah K, Dannenberg AJ. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in Cox-2-deficient mice. Cancer Res 2005;65:10113-10119.
Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 2005;105:4878-4884.
Huang S, Li Y, Podsypanina K, Chamorro M, Olshen AB, Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biology 2005;6:R84 [Epub ahead of print]
Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, VandenBrink MR. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood 2005;106:3285-3292. Epub 2005. Erratum in: Blood. 2006;107:38.
Hurria A, Brogan K, Panageas KS, Jakubowski A, Zauderer M, Norton L, Howard J, Hudis C. Change in cycle 1 to cycle 2 hematologic counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Drugs Aging 2005;22:709-715.
Hurria A, Gupta S, Zauderer M, Zuckerman E, Cohen HJ, Muss H, Panageas KS, Holland J, Saltz L, Kris MG, Noy A, Gomez J, Rodin M, Jakubowski A, Hudis C, Pearce C, Kornblith A. Developing a cancer specific geriatric assessment (CSGA): a feasibility study. Cancer. 2005;104:1998-2005.
Hurria A, Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Howard J, Hudis C, Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 2005; 22:785-791.
Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Zauderer M, Howard J, Hudis C. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treatment 2005; 92:151-156.
Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590-2597.
Ioannidis JPA, Bernstein J, Boffetta P, Danesh J, Dolan S, Hartge P, Hunter D, et al. A network of investigator networks in human genome epidemiology. Am J Epidemiol. 2005;162:302-304.
Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, Dematteo RP, D'angelica M, Koea J, Blumgart LH. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005;241:703-714.
Jarnagin WR, Klimstra DS, Hezel M, Gönen M, Fong Y, Roggin K, Cyrnes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B. Differential cell cycle regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables and clinical outcome. J Clin Oncol 2005; 23:1875-1884.
Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gönen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Therapy. 2005; [Epub ahead of print]
Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005;97:1705-1706.
Jimenez RE, Panageas KS, Busam KJ, Brady MS. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. J Clin Oncol 2005;23:518-524.
Kamel F, Engel LS, Gladen BC, Hoppin JA, Alavanja MC, Sandler DP. Neurologic symptoms in licensed private pesticide applicators in the agricultural health study. Environmental Health Perspectives 2005;113:877-882.
Kang D, Gridley G, Huang WY, Engel LS, Winn DM, Brown LM, Bravo-Otero E, Wu T, Diehl SR, Hayes RB. Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenetics Genomics 2005;15:343-347.
Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:1363-1370.
Kemeny N, Eid A, Stockman J, Gönen M, Schwartz L, Tetzlaff E, Paty P. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 2005;91:97-101.
Kemeny N, Gönen M. Hepatic arterial infusion after liver resection. (letter) N Engl J Med 2005;352:734-735.
Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, Dematteo R, Blumgart L, Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888-4896.
Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, van den Brink M, O'Reilly R, Pamer E, Satagopan J, Papanicolaou GA. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Annals of the New York Academy of Sciences 2005; 1062: 95-103.
Kim MJ, Holodny AI, Hou BL, Peck KK, Moskowitz CS, Bogomolny DL, Gutin PH. The effect of prior surgery on blood oxygen level-dependent functional MR imaging in the preoperative assessment of brain tumors. Am J Neuroradiol. 2005;26:1980-1985.
Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gönen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005; 23:1875-1884.
Kraus DH, Gönen M, Mener D, Brown AE, Bilsky MH, Shah JP. A standardized regimen of antibiotics prevents infectious complications in skull base surgery. Laryngoscope 2005;115:1347-1357.
Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, Kris MG, Heelan RT, Pizzo B, Tyson L, Sheehan C, Ross JS, Venkatraman E. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced non-small cell lung carcinoma. Cancer. 2005; 104:2149-2155
LaVigne EA, OliveriaA, Dusza SW, Geller AC, Halpern AC, Marghoob AA. Clinical and dermoscopic changes in common melanocytic nevi in school children: the Framingham Nevus Study. Dermatology. 2005;211:234-239.
Leliser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Apoptotic and cell cycle regulatory markers in uterine leiomyosarcomas. Gynecol Onc. 2005; [Epub ahead of print].
Liau KH, Ruo L, Shia J, Padela A, Gönen M, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer 2005 [Epub ahead of print].
Lyman S, Jones EC, Bach PB, Peterson MG, Marx RG. The association between hospital volume and total shoulder arthroplasty outcomes. Clin Orthop Relat Res 2005;(432):132-137.
Maluccio M, Covey AM, Gandhi R, Gönen M, Getrajdman GI, Brody LA, Fong Y, Jarnagin W, D'Angelica M, Blumgart L, Dematteo R, Brown KT. Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. J Vas Int Radiol 2005;16:955-961.
Mikhail M, Velasquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, Osman I. PTEN Expression in Melanoma: Relationships with Patients' Survival, Bcl-2 Expression, and Proliferation. Clin Cancer Res, 2005; 11:5153-5157.
Millikan RC, Hummer AJ, Wolff MS, Hishida A, Begg CB. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat. 2005;89:309-312.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-524.
Mitra N, Indhurkya A. A propensity-score approach to estimating the cost-effectiveness of medical therapies from observational data. Health Econ 2005;14:805-815.
Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1-->3), (1-->4)-D-beta-glucan. Leuk Res. 2005; 29:679-683.
Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical Breast Cancer 2005; 6:55-60.
Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, VanPoznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005; 2396:483-487.
Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res and Treatment 2005; 90:157-163.
Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI. Flurodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210-3216.
Moskowitz CH, Zelenetz AD, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldworth J, Olshen A, Chaganti R, Nimer S. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed an refractor DLBCL. Blood. 2005;106;3383-3385.
Mourton SM, Chi DS, Sonoda Y, Alektiar KM, Venkatraman ES, Barakat RR, Abu-Rustum NR. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies. Gynecol Onc. 2005; [Epub ahead of print]
Olshen AB, Cosman PC, Rodrigo AG, Bickel PJ, Olshen RA. Vector quantization of amino acids: analysis of the HIV V3 loop region. J Stat Plan Infer 2005;(1-2):277-298.
Olson SH, Iyer S, Scott J, Erez O, Samuel S, Markovits T, Schwartz M, Toro C, Lau N, Gambarin-Gelwan M, Kurtz RC. Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Quality of Life Outcomes 2005;3:39.
Omuro AMP, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed neurotoxicity in primary central nervous system lymphoma Arch Neurol 2005;62:1595-1600.
Orlow I, Berwick M, Hummer A, Begg CB. Absence of Association of CDKN2A Ala148Thr with Breast Cancer. J Med Genet (e-letter) July 4th 2005
Panageas KS, Elkin EB, DeAngelis LM, Ben Porat L, Abrey LE. Trends in survival from Primary Central Nervous System Lymphoma 1975-1999: a population-based analysis. Cancer, 2005;104:2466-2472.
Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res. 2005;11:1999-2007.
Peterlongo P, Mitra N, Chuai S, Kirchoff T, Palmer C, Huang H, Nafa K, Offit K, Ellis NA. Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. Int J Cancer 2005;114:505-507.
Pham HH, Schrag D, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. JAMA 2005;294:473-481.
Phelan DL, OliveriaA, Halpern AC. Patient experiences with photo books in monthly skin self-examinations. Dermatol Nurs 2005;17:109-114.
Pinto JT, Van Raamsdonk J, Leavitt BR, Hayden MR, Thaler HT, Krasnikov BF, Cooper AJL. Treatment of YAC128 mice and their wild-type litter mates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J Neurochem 2005; 94:1087-101.
Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, Barakat RR. Percutaneous endoscopic gastrostomy (PEG) tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005;96:330-334.
Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora L, Scardino PT, Koutcher JA, Zakien KL. Correlation of MR imaging and spectroscopy with step section histopathology in prostate cancer after external beam radiation therapy -initial exploratory analysis. Radiology 2005;236:545-553.
Raizer JJ, Koutcher JA, Abrey LA, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian K. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol. 2005;71:173-180.
Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005;3:8076-8080.
Robbins RJ, Wan Q, Grewal RK, Reibke R, Gönen M, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time Prognosis for Metastatic Thyroid Carcinoma Based on FDG-PET Scanning. J Clin Endocrinol Metab 2005; [Epub ahead of print]
Roggin KK, Yeh JJ, Ferrone CR, Riedel E, Gerdes H, Klimstra DS, Jaques DP, Brennan MF. Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol 2005;12:971-980. [Epub ahead of print].
Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol 2005;23: 4146-4151.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen Y-T, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of National Academy of Sciences 2005;102:18538-18543.
Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-5232.
Schoder H, Hermann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher H, Larson SM. 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11:4761-4769.
Schoder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive Non-Hodgkin's Lymphoma. J Clin Oncol 2005; [Epub ahead of print]
Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224.
Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population. Urology 2005;65:1118-1125.
Schrag D, Weiser M, Schattner M, Shia J, Akhurst T. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol 2005;23:1799-1802.
Schrag D. Discussing drug costs with patients. Clinical Advances in Hematol Oncol 2005;3:525-526.
Secin FP, Karanikolas N, Kuroiwa K, Vickers A, Touijer K, Guillonneau B. positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy. Eur Urology 2005; 48:786-792
Sen S, Satagopan JM, Churchill GA. Quantitative trait locus study design from an information perspective. Genetics 2005;170:447-464.
Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher H, Koff A. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci U S A. 2005;102:210-215.
Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, Gönen M, Schwartz GK. Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. Clin Cancer Res 2005;11:3296-3302.
Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gönen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clin Cancer Res 2005;11:3836-3845.
Shah NT, Kris MG, Miller VA, Tyson LB, Pizzo BM, Heinemann M-H, Ben Porat L, Halpern A, Heelan RT. Practical management of patients with non-small cell lung cancer treated with Gefitinib (IressaTM, ZD1839). J Clin Oncol 2005;23:165-174.
Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11:8669-8673.
Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, FowlerR, FinnP, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
Spanknebel K, Coit DG, Bieligk SC, Gönen M, Rosai J, Klimstra DS. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis. Am J Surg Pathol 2005;29:305-317.
Specht, Kattan MW, Gönen M, Fey J, VanZee KJ. Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. Ann Surg Oncol 2005;12:654-659.
Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate cancer recurrence after radical prostatectomy. Cancer 2005;104:290-298.
Stier E, Freeman-Wang T, Hochberg L, Hummer A, Venkatraman E, Walker P. Using the cone biopsy to compare colposcopy clinics in New York and London. J Low Genital Tract Dis 2005;2:106-111.
Tao Y, Klause A, Vickers A, Bae K, Ellis M. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 2005;95:91-95.
Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, Schrag D, Wong WD. The development of a validated instrument to evaluate bowel function after sphincter preserving surgery for rectal cancer. Dis Colon Rectum 2005;48:1353-1365.
Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MR. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005;106:3322-3330.
Thomson CD, McLachlan SK, Grant AM, Paterson E, Lillico AJ. The effect of selenium on thyroid status in a population with marginal selenium and iodine status. Brit J Nutrit 2005;94:962-968.
Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent S. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opinion on Drug Safety 2005;4:779-794.
Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Intl J Radiat Oncol Biol Physic 2005:62:752-760.
Vickers AJ, Bianco FJ, Boorjian S, Scardino P, Eastham JA. Does delay between diagnosis and radical prostatectomy increase the risk of cancer recurrence? Cancer 2005 [Epub ahead of print].
Vickers AJ, Feinstein MB, Deng GE, Cassileth BR Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial (ISRCTN89462491). BMC Palliative Med 2005;4:5
Vickers AJ. Analysis of variance is easily misapplied in the analysis of randomized trials: a critique and discussion of alternative statistical approaches. Psychosomatic Med 2005;67:652-655.
Vickers AJ. How to interpret data from randomized trials. The Scandinavian prostatectomy study illustrates two common errors. Nature Clinical Practice. Urology 2005;9:2-3
Vickers AJ. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Med Res Methodol 2005;5:35
Vural B, Chen LC, Saip P, Chen YT, Ustuner Z, Gönen M, Simpson AJ, Old LJ, Ozbek U, Gure AO. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer. 2005; [Epub ahead of print]
Yanke BV, Gönen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005;173:421-424.
Yeung HW, Schoder H, Smith A, Gönen M, Larson SM. Clinical Value of Combined PET/CT Imaging in the Interpretation of FDG PET Studies in Cancer Patients. Mole Imaging Biol 2005; 7:229-235.
Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW. Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. J Immunol 2005;174: 758-766.
Zaider M, Zelefsky MJ, Cohen GN, Chui C, Yorke ED, Ben-Porat L, Happersett L. Methodology for biologically-based treatment planning for combined low dose-rate (permanent implant) and high dose-rate (fractionated) treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2005;61:702-713.
Zakian K, Thaler HT, Fong Y, Koutcher J. Liver regeneration in man is characterized by significant changes in cellular phosphorous metabolism: assessment using proton-decoupled 31P - magnetic resonance spectroscopic imaging. Magn Reson Med 2005;54:264-271.
Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 2005;104:719-729.
Zauber A, Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Habbema JDK, Winawer S. US colorectal cancer mortality can be reduced 33% by 2010 only with intensive utilization of current CR screening tests, lifestyle risk factor modifications and treatment dissemination. Gastroenterology (Digestive Disease Week) 2005.
Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Michelman-Lo S, Healey J, Huvos AG, Meyers P, Gorlick R. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005;44638-44642.
Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005;23:826-831.
Zhao B, Schwartz LH, Moskowitz CS, Wang L, Ginsberg MS, Cooper CA, Kalagian JP. Pulmonary metastases: effect of CT section thickness on measurement--initial experience. Radiology 2005;234:934-939.
